|Mr. Donald J. McCaffrey||Co-Founder, Chairman, Chief Exec. Officer, Pres and Sec.||676.24k||N/A||N/A|
|Mr. Aaron Bradley Cann CA, CPA, CBV||Chief Financial Officer||322.97k||N/A||N/A|
|Mr. Kenneth Eugene Lebioda BA||Sr. VP of Bus. & Corp. Devel.||304.62k||N/A||N/A|
|Dr. Jan O. Johansson M.D., Ph.D.||Sr. VP of Medical Affairs||315.72k||N/A||N/A|
|Dr. Michael Sweeney M.D.||Sr. VP of Clinical Devel.||628.59k||N/A||56|
Resverlogix Corp., a clinical stage biotechnology company, develops small molecule therapeutics for Bromodomain and ExtraTerminal (BET) inhibition. The company is developing apabetalone (RVX-208), a small molecule selective BET domain inhibitor that is in clinical trials for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, Alzheimers disease, and orphan diseases. Resverlogix Corp. is headquartered in Calgary, Canada.
Resverlogix Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.